Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 4,092 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Combination Agent 1 Clear all

Conditions: Carcinoma, Non-Small Cell Lung
Interventions: CPG 7909, Chemotherapy; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 17
States / cities: Gilroy, California • Los Angeles, California • Palm Springs, California + 14 more

Conditions: Advanced Solid Tumors
Interventions: VVD-130037, Docetaxel, Paclitaxel, Pembrolizumab; Drug
Lead sponsor: Vividion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 8
States / cities: Jacksonville, Florida • Sarasota, Florida • Tampa, Florida + 5 more

Conditions: Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
Interventions: Idelalisib, Nab-paclitaxel, mFOLFOX6; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 9
States / cities: Scottsdale, Arizona • Los Angeles, California • Aurora, Colorado + 6 more

Conditions: Non-Small Cell Lung Cancer ALK-positive, Non-Small Cell Lung Cancer c-Met Dependent, Non-Small Cell Lung Cancer ROS Marker Positive, Systemic Anaplastic Large-Cell Lymphoma, Advanced Malignancies Except Leukemia
Interventions: PF-02341066, Rifampin, Itraconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 596 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 24
States / cities: Orange, California • Aurora, Colorado • Chicago, Illinois + 8 more

Conditions: Nonfluent Aphasia, Stroke
Interventions: levodopa/carbidopa, Placebo comparator; Drug
Lead sponsor: Shirley Ryan AbilityLab; Other
Eligibility: 21 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hematologic Malignancies, Acute Myeloid Leukemia, Lymphoid Leukemia, Chronic Myeloid Leukemia, Hodgkin's Disease, Non-Hodgkin's Lymphoma, Myelodysplastic Syndromes
Interventions: StemEx®; Drug
Lead sponsor: Gamida Cell -Teva Joint Venture Ltd.; Other
Eligibility: 12 Years to 55 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 16
States / cities: Los Angeles, California • Orange, California • Aurora, Colorado + 10 more

Conditions: Delirium, Lumbar Radiculopathy, Lumbar Osteoarthritis, Lumbar Spine Disc Degeneration
Interventions: Light sedation with propofol, Induction with propofol, Maintenance anesthetic using a volatile anesthetic, Muscle relaxant during maintenance anesthesia, Pain control with fentanyl, Bispectral Index (BIS) monitoring for depth of anesthesia, Spinal Anesthesia, Midazolam administered during spinal anesthesia, Cerebrospinal fluid collection, Administration of intrathecal morphine; Procedure
Lead sponsor: Johns Hopkins University; Other
Eligibility: 65 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms, Neoplasms by Histologic Type, Neoplasms, Clear-cell Metastatic Renal Cell Carcinoma, Melanoma, Triple Negative Breast Cancer, Bladder Cancer, Head and Neck Cancer, Non-small Cell Lung Cancer
Interventions: Combination of Varlilumab and Atezolizumab; Drug
Lead sponsor: Celldex Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • New York, New York + 1 more

Conditions: Leukemia
Interventions: imatinib mesylate, adjuvant therapy; Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 2
States / cities: Duarte, California • Seattle, Washington

Conditions: Advanced Metastatic Melanoma
Interventions: Cabozantinib, Pembrolizumab; Drug
Lead sponsor: John Rieth; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Multiple Myeloma
Interventions: GPC-100, Propranolol, G-CSF; Drug
Lead sponsor: GPCR Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: La Jolla, California • Gainesville, Florida • Indianapolis, Indiana + 7 more

Conditions: Solid Cancers
Interventions: Atezolizumab, Bevacizumab, Interferon alfa-2b, Ipilimumab, Obinutuzumab, PEG-interferon alfa-2a; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 8
States / cities: Scottsdale, Arizona • Los Angeles, California • New Haven, Connecticut + 3 more

Conditions: Myelofibrosis With Myeloid Metaplasia, Myeloid Metaplasia, Myelofibrosis
Interventions: Pomalidomide, Prednisone, Placebo to pomalidomide, Placebo to prednisone; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 6
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York + 2 more

Conditions: Advanced Cancer
Interventions: AGEN1777, a PD-1 inhibitor; Drug
Lead sponsor: Agenus Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Grand Rapids, Michigan • Southfield, Michigan • Cincinnati, Ohio + 4 more

Conditions: Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis
Interventions: MK-8527, FTC/TDF, Placebo to MK-8527, Placebo to FTC/TDF; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 16 Years and older
Enrollment: 4,390 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Mobile, Alabama • Los Angeles, California + 20 more

Conditions: Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
Interventions: Trametinib, Hydroxychloroquine; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Astrocytic Tumors, Glioblastoma Multiforme, Anaplastic Astrocytoma, Brain Tumor
Interventions: Cohort 1, Cohort 2, Cohort 3, Antibiotics; Biological · Drug
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Oral Surgery
Interventions: Vicodin, Dexamethasone; Drug
Lead sponsor: Boston University; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV, HIV Infections
Interventions: COBI, RTV, ATV, FTC/TDF, COBI placebo, RTV placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 698 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 64
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more

Conditions: Metastatic Hormone-Sensitive Prostate Cancer
Interventions: PROSTVAC-V, PROSTVAC-F, Nivolumab, Ipilimumab, Neoantigen DNA vaccine, TriGrid Delivery System, Tumor biopsy, Peripheral blood, Fecal samples, Leukapheresis; Biological · Drug · Device + 1 more
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Myeloma
Interventions: MAGE-A3, MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY; Biological
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 70 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage II Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage III Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Ann Arbor Stage IV Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Interventions: Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Nivolumab, Prednisone, Quality-of-Life Assessment, Rituximab; Drug · Biological · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV-1-infection
Interventions: Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 577 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 51
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more

Conditions: Solid Tumor
Interventions: Epacadostat, Pembrolizumab, Oxaliplatin, Leucovorin, 5-Fluorouracil, Gemcitabine, nab-Paclitaxel, Carboplatin, Paclitaxel, Pemetrexed, Cyclophosphamide, Cisplatin, Investigator's choice of platinum agent; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 16
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more

Search by objective public record fields.

CPG 7909 Injection in Non-Small Cell Lung Cancer

A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors

Study of Single Agent Idelalisib Followed by Idelalisib in Combination With Chemotherapy in Adults With Metastatic Pancreatic Ductal Adenocarcinoma

A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Augmenting Language Therapy for Aphasia: Levodopa

Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy

Shaping Anesthetic Techniques to Reduce Post-operative Delirium

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia

Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

A Study Investigating AGEN1777 in Participants With Advanced Solid Tumors

A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)

Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).

Phase I Study of Safety and Immunogenicity of ADU-623

Pilot Study: Effect of Dexamethasone vs Vicodin in Reducing Post-operative Pain

Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

Neoantigen DNA Vaccine in Combination With Nivolumab/Ipilimumab and PROSTVAC in Metastatic Hormone-Sensitive Prostate Cancer

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapy

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy

A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)